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Family physicians are responsible for diagnosing and treating the majority of people with
type 2 diabetes mellitus and co-morbid depression. As a result of the impact of co-morbid
depression on patient self-care and treatment outcomes, screening for depression in the
context of a structured approach to case management and patient follow up is recom-
mended in people with diabetes and cardiovascular disease. This review summarizes the
need for improved recognition and treatment of depression in diabetes; and makes expert
recommendationswith regard to integrating screening tools and therapies into a busy family
or general medical practice setting.
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1. Introduction
Depression and diabetes mellitus are two commonly encoun-
tered clinical conditions in primary care [1]. People with
type 2 diabetes are commonly diagnosed and largely man-
aged in the primary care setting, with fewer of them being
referred for specialist care [2]. Co-morbid depression wors-
ens glycemic control, and is associated with more severe and
rapid development of complications, but is often undiagnosed
and untreated [3–6]. Many of the somatic symptoms of depres-
sion (e.g. appetite change resulting in weight gain or loss, loss
of energy and difﬁculty concentrating) could be attributed to
diabetes making it difﬁcult to ascertain any speciﬁc contri-
bution of co-morbid depression (Table 1). Minor (subclinical)
depression has been used to describe the presence of depres-
sive symptoms, which are not severe enough to warrant a
diagnosis of clinical depression according to standard criteria.
Questions concerning which screening instrument to use,
whether these instruments require speciﬁc competencies,
who to screen, andhowoften, are common.Theyare also com-
plex and in some cases difﬁcult questions to answer; however,
with the growing numbers of patients seen in primary care,
there is an urgent need for practical advice. This review sum-
marizes the need for improved recognition of depression in
diabetes, and makes recommendations based on expert opin-
ion, with regard to integration of screening in routine primary
Table 1 – Symptoms and signs of depression, anxiety,
panic disorder and diabetes distress.
Depression
Major depressive disorder (clinical depression)
Severely depressed mood that persists for at least two weeks in
conjunction with 5 of the following symptoms/signs for at least 2
weeks:
- Loss of pleasure
- Changes in sleep pattern (insomnia/hypersomnia)
- Early rising
- Changes in appetite with weight loss/gain
- Feelings of guilt of worthlessness
- Low energy level
- Difﬁculty concentrating
- Nervousness
- Morning sadness
Episodes may be isolated or recurrent.
Episodes may be categorized as mild (few symptoms in excess of
minimum criteria), moderate, or severe (marked impact on social
or occupational functioning).
Episodes with psychotic features are rated as severe.
Minor depressive disorder (subclinical depression)
Depressed mood in conjunction with 2–4 of the aforementioned
depressive symptoms/signs for at least 2 weeks.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
care. The emphasis is on pragmatic solutions to efﬁciently
detect andmanagepatientswith co-morbiddepressionand/or
distresswithin the conﬁnes of a busy generalmedical practice.
It should be borne in mind, however, that screening in the
absence of a structured approach to case management, has
not been shown to be effective.
2. Depression and diabetes
Depression is commonly identiﬁed in association with a
number of chronic medical illnesses, and is most strongly
associated with diabetes mellitus [7]. Clinical depression
reportedly occurs in up to 13% and 18% of people with type
1 and type 2 diabetes [8,9]. Particularly vulnerable groups
include female patients [4,10–12], those diagnosed with dia-
betes at a younger age [10–12], with high body mass index
[10], poor glycemic control [10,12,13], complications [4,10,14],
lower levels of education, household earnings [11], or requiring
social support [4,12].
The association between depression and diabetes may be
bi-directional meaning that diabetes may lead to the devel-
opment of depression or vice versa [15,16]. Diabetes has been
shown to be one of the most psychologically and behaviorally
demanding medical illnesses [17]. Although early diabetes
may be largely asymptomatic, the threat or eventual develop-
ment of long term complications, and the progressively more
complex treatment regimens employed to maintain glycemic,
lipid and blood pressure control in order to prevent these late
complications, are perceived as a burden by the patient and
may predispose to depression. Patients often report feelings of
fear, anger, resentment and devastation at the time of diagno-
sis; and feelings of social isolation are evident throughout all
stages of disease [18]. Feelings of vulnerability are also known
to increase with longer diabetes duration and the appearance
of complications [19,20]. Conversely, there is an increased risk
of depressed people developing diabetes [15,21–23], with most
but not all of the risk being attributed to lifestyle factors [15].
Depressed patients aremore likely to lead a sedentary lifestyle
[24,25], have a poor diet [25] and smoke [24,25], all of which are
known risk factors for the development of type 2 diabetes.
Depression in people with diabetes has been shown to
be associated with worse metabolic and glycemic control
[26], more severe and rapid development of micro- and
macro-vascular complications [27], and >2 fold higher risk of
all-cause mortality [28–30] compared to people with diabetes
without co-morbid depression. The estimated contribution
of depression to mortality is comparable to that of cardio-
vascular disease among an older (≥60 years) primary care
patient cohort with diabetes [31]. While co-morbid depression
and diabetes have been speciﬁcally linked to increased risk
of cardiovascular mortality [14,32], strong associations with
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on-cardiac, non-cancer related mortality have also been
eported [33].
People with co-morbid diabetes and depression also have
igniﬁcantly worse quality of life relative to people with
epression alone, diabetes alone, or non-depressed non-
iabetic individuals [34–36]. In addition, people with diabetes
nd co-morbid depression report signiﬁcantly greater num-
er of sick days, have longer duration hospital stays and
ore frequent hospital admission compared to people with
iabetes alone [6]. Without taking into account lost produc-
ivity [37], co-morbid depression is associated with a 4.5-fold
ncreases in health expenditure [38]. In addition, clinically
epressed people with diabetes are more likely to have prob-
ems with medication [26,39,40]. Recent evidence suggests
hat sub-clinical depression is associated with worse self-care
ehavior including, which may affect all aspects of treatment,
ncluding diet [17,39,41–44], exercise [41,42,44,45], medication
17,26,39,41,42,45], and blood glucose monitoring [45]. Since
ndividuals with diabetes perform the vast majority of routine
aily care, self-care represents a critical element in dia-
etes management. Therefore, improved recognition and case
anagement in comorbid depression may not only improve
atient quality of life, but also lead to improvements in patient
elf-care behavior and reduced health care costs [17,38,46,47].
Table 2 – Commonly used questionnaires used in the diagnosis
with co-morbid diabetes.
Depression
World Health Organization (WHO)-5 Well-Being Index
5 items scoring of 0–5 based on the extent to which the respondent agrees
depression.
In order to monitor possible changes in well-being, the percentage score is
score by 4. A 10% difference indicates a signiﬁcant change.
Becks Depression Inventory (BDI)
21 item self-report multiple choice questionnaire relating to
cognitive and somatic symptoms of depression occurring in the
previous 7 days. Each response is scored 0–3 with higher values
for more intense symptoms, and then summed with total scores
of ≥10 commonly used to indicate depression
Center for Epidemiologic Studies Depression (CES-D) Scale
20 item self-report scale rated on a 4-point scale indicating the
frequency of occurrence of each item in the previous week (0 –
rarely/none to 3 – most/all). Scores are summed with ≥16
indicating depression.
Hospital Anxiety and Depression (HADS) Scale
Measures symptoms of anxiety and depression in patients with
somatic complaints. It comprises of 14 items, with half the items
addressing depression and the other half, anxiety. Answers score
0–3 and are evaluated as two sum scores between 0 and 21. Scores
≥11 are considered clinically relevant.
Patient Health Questionnaire (PHQ)-9
9 item questionnaire with each item scoring 0–3 based on the
frequency of symptoms. Severity of depression as follows: 5–9
(mild), 10–14 (moderate), 15–19 (moderately severe), and 20–27
(severe). PHQ-8 variant used in epidemiological studies omits a
single question regarding suicidal ideation. PHQ-2 has also been
studied with a score ≥3 out of a possible 6 identiﬁed as the
optimal threshold for the diagnosis of major depression.s 7 ( 2 0 1 3 ) 1–10 3
3. Screening for depression and distress
Screening for depression in people with diabetes remains con-
troversial, andmanyquestions regarding the optimal choice of
screening instrument still remain. Screening was introduced
in the UK in 2006, but results have been mixed with variable
improvements in rates of detection and changes to clinical
practice in rural and semi-rural communities [48,49]. Closer
relationships between care-givers and their patients may
compensate for the need to implement screening in these
practices [50], but other factors will also inﬂuence the util-
ity of screening for co-morbid depression. These include (1)
selecting the most sensitive and speciﬁc test, (2) broadening
the scope of intervention to patients with milder depression,
anxiety or emotional distress [16,51–53], and importantly, (3)
integrating screening of depression with proven cost-effective
treatment strategies.
The current levels of undiagnosed depression support the
notion that reliance on the presentation and recognition
of patient symptomatology is inadequate [54]. To this end,
there exist a number of previously validated self-assessment
questionnaires to assist in the identiﬁcation of depression
and/or anxiety and distress (Table 2). Several self-assessment
of depression, anxiety, distress and well-being, in people
Distress/well-being
with the statement. A score of <13 indicates likely clinical
used. The percentage value is obtained by multiplying the
Problem Areas in Diabetes (PAID)
Designed to assess the general emotional burden of diabetes
and distress related to treatment and lifestyle. The PAID-20
comprises 20 items scored on a 5-point scale which are
summed, giving a total score of 0–100 with higher scores
indicating greater levels of distress and worse quality of life. A
5 item (PAID-5) and 1 item (PAID-1) are also available.
Well-Being Questionnaire (WBQ)
22-item questionnaire designed speciﬁcally for use in people
with diabetes, and used to assess categories of depression,
anxiety, fatigue, and positive well-being with a focus on
cognitive rather than somatic symptoms, the latter being
potentially overlapping with symptoms of diabetes. Scores in
each category are evaluated separately.
bet4 pr imary care d ia
questionnaires have been compared for use as screening tools
for depression and distress in diabetes [54,55]. These ques-
tionnaires can increase sensitivity for diagnosis of depression
by up to 90% [54]. In the context of a busy clinical practice,
the ideal screening questionnaire should (1) comprise an easy,
acceptable and intuitive self-assessment, and (2) be brief so
that it can be completed in an outpatient waiting room or
during the consultation if necessary.
The World Health Organization (WHO)-5 Well-Being Index
is suitable in all people with diabetes. A study compar-
ing the WHO-5 with the longer Center of Epidemiological
Studies-Depression Scale CES-D showed moderate agree-
ment between the two instruments [56]. However, unlike the
other screening instruments for depression, the WHO-5 pro-
vides clinicians with a continuous measurement of positive
Table 3 – Summary of recommendations for screening for co-m
effective cognitive behavioral therapeutic intervention.
WHO-5 Well-Being Index (1998 version)
Please indicate for each of the five statements which are closest to ho
over the last two weeks. Notice that higher numbers mean better well-
Example: If you have felt cheerful and in good spirits more than half of
weeks, put a tick in the box with the number 3 in the upper right corner
Over the last two weeks
All of
the time
Most of 
the
time
More than
half of the
time
Less th
half of 
time
I have felt cheerful and in 
good spirits
5 4 3 2
I have felt calm and 
relaxed
5 4 3 2
I have felt active and 
vigorous
5 4 3 2
I woke up feeling fresh 
and rested
5 4 3 2
My daily life has been 
filled with things that 
interest me
5 4 3 2
Scoring:
The raw score is calculated by summing the scores. The raw score ran
representing worst possible and 25 representing best possible quality 
To obtain a percentage score ranging from 0 to 100, the raw score is m
PAID-5 and PAID-1 
Which of the following diabetes issues is currently a problem for you?
Circle the number that gives the best answer for you. 
Please provide an answer for each question. 
Not a 
problem
Minor 
problem
Moderate
problem
Feeling scared when you think 
about living with diabetes
0 1 2
Feeling depressed when you 
think about living with diabetes
0 1 2
Worrying about the future and 
the possibility of serious 
complications
0 1 2es 7 ( 2 0 1 3 ) 1–10
well-being which can be monitored over time in addition
to detecting depression with reasonable sensitivity. Other
depression screening instruments, such as the Patient Health
Questionnaire (PHQ)-9, only indicate whether or not a patient
has likely clinical depression (i.e. the best measure of posi-
tive well-being with these screening instruments is that the
patient is not depressed). Furthermore, the WHO-5 only com-
prises 5 questions, is therefore less time consuming, and is
freely available in a multitude of languages.
Inclusion of a screening for diabetes distress, such as Prob-
lem Areas in Diabetes (PAID)-5 questionnaire, which focuses
on emotional responses (distress) to aspects of life with dia-
betes, provides considerable additional value (Table 2). In the
absence of major depression, the tool helps identify the extent
to which any sub-threshold depressive symptoms may be
orbid depression and emotional distress and providing an
w you have been feeling 
being.
 the time during the last two 
.
an
the
Some of
the time
At no time
1 0
1 0
1 0
1 0
1 0
ges from 0 to 25, 0 
of life.
ultiplied by 4. 
 
 Somewhat 
serious 
problem
Serious 
problem
3 4
3 4
3 4
pr imary care d iabetes 7 ( 2 0 1 3 ) 1–10 5
Table 3 – (Continued )
Feeling that diabetes is taking up 
too much of your mental and 
physical energy every day
0 1 2 3 4
Coping with complications of 
diabetes 0 1 2 3 4
The shaded question is the PAID-1.
We recommend using the PAID-1 as follows. Administer the screening item. If the response is 3 or 
higher, administer the remaining questions on the PAID-5 or the full 20 item PAID. For the PAID-
5, a total score of ≥8 indicates possible diabetes-related emotional distress that warrants further 
assessment. On the full 20 item PAID, a score of >33 has been suggested as indicative of likely 
emotional distress and a score of 38 is indicative of possible depression. In each case, further 
assessment is warranted. 
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melated to diabetes. In these instances, there is emerging evi-
ence that early treatment may prevent the development of
ore severe depression [51,52]. In the presence of depression,
he same tool assesses whether or not the patient is also dis-
ressed with their diabetes. Patients with co-existent diabetes
istress need much more focus on medical disease manage-
ent, whereas depressed patients with low levels of diabetes
istress can bemore appropriatelymanaged via existingmen-
al health referral pathways.
The combined approach of using the WHO-5 question-
aire (for depression) in combination with either the PAID-5
r PAID-1 questionnaire (for diabetes distress) is a simple tool
or detecting depression, monitoring patient well-being over
ime, andguiding the extent towhich the subsequentmanage-
ent of depressive symptoms should focus on speciﬁc aspects
elated to diabetes management (Table 3). It is important to
mphasize that patients meeting the criteria for suspected
linical or subclinical depression need clinical veriﬁcation
f the diagnosis and severity (including assessment of sui-
idal ideation, psychosis and bipolar manifestation) through
ppropriate history taking and symptom enquiry. The differ-
ntial diagnoses of general anxiety disorder, panic disorder
nd/or an underlying eating disorder should also be consid-
red. Following veriﬁcation of depression, other etiologies for
epression such as dementia, alcoholism and hypothyroidism
hould be excluded.
. Stepped care model of treating
epression
ith the increasing demands being placed on primary care,
he growing numbers of people with diabetes and the high
revalence of co-morbid depression, it is equally important
hat patients who screen positive are managed appropriately
nd efﬁciently. Stepped care models build on the efﬁciency
odel whereby the least restrictive and least costly interven-
ions are provided prior to higher intensity care. This reduces
he risk of those people not in need of intensive treatment
eceiving too much care whilst ensuring that sufﬁcient care
s provided to all patients. Since the detection and treat-
ent of minor depression has been shown to prevent severedepression and is cost saving [51–53], the starting point for
the ideal depression stepped care model is a highly sensitive
screening tool. Having identiﬁed depression, the stepped care
model can subsequently guide management ranging from
watchful waiting to collaborative care and/or referral to men-
tal health services formore severely depressedpatients (Fig. 1).
Fortunately, about 30–40% of patients recover from depression
without intervention. This means that it would be inefﬁcient
and unnecessary to provide all individuals with active treat-
ment. The ﬁrst step for people with minor depression is,
therefore, to monitor symptoms over the course of the ensu-
ing 8–12-weeks and then re-evaluate. This watchful waiting
does not, however, preclude providing patients with advice
and information on how to stay physically and mentally ﬁt.
For those patients requiring intervention, the avail-
able treatment for depression can be broadly classiﬁed
into cognitive-behavioral (CBT) and pharmacological. CBT is
proven to be an effective treatment for people with diabetes
patients and co-morbid depression, with improved remis-
sion rates and glycemic control relative to placebo [57]. Until
recently, access to CBT has been limited [57]; however, inno-
vations such as web-based CBT provide new opportunities
to large volumes of patients with minor depressive symp-
toms using minimal resources [58]. Although attrition rates
of web-based CBT are a problem, anchoring web-based pro-
grams within the existing primary care infrastructure (for
example, by allowing practice nurses to administer, follow and
conclude such programs with patients) may improve patient
self-care behavior. Group CBT might also be used in less
severe depressive states as stand-alone treatment. CBT may
also avert the use of pharmacological treatments, which can
interfere with diabetes management. CBT is the treatment of
choice in patients who are unable to tolerate pharmacologi-
cal treatment, and may also be provided in combination with
pharmacotherapy in more severe cases [59].
Of the available pharmacological treatments, selective
serotonin reuptake inhibitors (SSRIs) are the most commonly
prescribed in patients with co-morbid depression (55% of the
cohortwith depression and diabetes) [60]. However, there have
been only a handful of randomized controlled trials assessing
the role of anti-depressant drug treatment in people with dia-
betes and depression [61–66]. All except one of these trials
6 pr imary care d iabetes 7 ( 2 0 1 3 ) 1–10
Fig. 1 – Diabetes and co-morbid depression stepped care model (adapted from guidelines issued by National Institute of
Clinical Excellence [76]). 1Complex depression includes depression that shows an inadequate response to multiple
treatments, is complicated by psychotic symptoms, and/or is associated with signiﬁcant psychiatric comorbidity or
psychosocial factors. 2Collaborative care – patient deﬁned problems are identiﬁed alongside medical problems, focus on
jointly developed goals, self-management training and support, and sustained follow-up provided in conjunction with an
assigned case manager (e.g. practice nurse) in liaison with the psychiatrist, primary care practitioner and psychologist.evaluatedSSRIs (sertraline 50–200mg/d, ﬂuoxetine 20–40mg/d
and paroxetine 20mg/d) and all 3 agents were found to be
effective in reducing depressive symptoms relative to placebo
after 10 weeks of treatment [62,64]. Fluoxetine and paroxetine
have been compared in a single trial, and were both equally
effective [64]. Whilst a couple of studies have reported trends
to improved glycemic control with ﬂuoxetine [61,64], only one
trial of sertraline was found to signiﬁcantly improve glycemic
control relative to the placebo group after 6 months of treat-
ment [67]. In this study, baseline HbA1c improved from 10.0%
to 8.0% in the sertraline treated group versus 9.7% to 8.8% in
the placebo group (p<0.01). Aggregating sertraline data from
two published trials involving 387 patients showed 85% of
people with diabetes met criteria for psychiatric symptom
improvement, with full remission of clinical depression occur-
ring in 46% of patients, following 16-weeks of treatment [63].
The presence of diabetes complications andhigher depression
scores at baseline were found to be predictive of non-response
to treatment [63]. Bryan et al. [1] compared the rates of depres-
sion remission in people with and without diabetes receiving
another SSRI, citalopram (n=235 and n=2641, respectively).
The majority of patients received at least 40mg/d, and was
treated for ≥8 weeks irrespective of the presence of co-morbid
diabetes. As is generally recognized in cases of depression
associated with medical co-morbidity, rates of remission were
lower for the people with diabetes.
Collaborative care, whereby patients work together with
nurses and primary care physicians toward individualized
treatment goals, has recently been shown to improve glycemiccontrol, self-care, quality of life and treatment satisfaction
in people with diabetes and/or coronary heart disease with
co-morbid depression [68]. In this study, collaborative care
comprised structured visits with primary care nurses every
2–3 weeks focusing on management of depression, the med-
ical disease, and self-care activities; this included providing
problem solving assistance and goal setting. A psychiatrist,
primary care physician, and psychologist together with the
nurse reviewed cases on a weekly basis. The intervention
group recorded signiﬁcant improvement in both medical out-
comes (HbA1c, LDL cholesterol and systolic blood pressure)
and depression, when compared to the control group. In this
way, the combined approach to depression and medical man-
agement can effectively impact both psychiatric and somatic
outcomes whilst making best use of available human health-
care resources.
A meta-analysis of all randomized controlled trials eval-
uating interventions for depression in diabetes [including
CBT, pharmacological, and collaborative (enhanced care)
approaches] has recently been published [69]. The pooled
results indicated that these interventions resulted in improve-
ment of depressive symptom severity (moderate effect size,
−0.512; 95% CI −0.633 to −0.390) and HbA1c (small effect size,
−0.274; 95% CI −0.402 to −0.147). The group concluded that
the collaborative care trials were more representative of a gen-
eral primary care population and that the more modest effect
size on combined outcomes of depression and glycemic con-
trol (−0.292; 95% CI −0.429 to −0.155) would more likely reﬂect
clinical reality.
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. Prevention
hile depressed patients are more likely to report lower self-
are ability and have less perceived ability to manage conse-
uences of diabetes, depressedpatients havenodemonstrable
ifferences in knowledge of their condition relative to non-
epressed diabetes patients [70]. These ﬁndings suggest that
ducational programs focusing only on information transfer
lone, would be insufﬁcient in preventing susceptible indi-
iduals from becoming depressed and is unlikely to improve
ood in depressed patients [71]. However, Diabetes Educa-
ion and Self-Management for Ongoing and Newly Diagnosed
DESMOND), which is a structured group educational program
sing CBT techniques to enhance learning and improve self-
are in people with type 2 diabetes has been shown to reduce
epression scores during 12 months follow-up [72]. Other
reventative strategies employing preemptive nurse led psy-
hiatric consultation have also been successfully employed in
igh risk medically complex people with diabetes [73].
. Conclusions
his review summarizes the importance of timely and appro-
riate screening, diagnosis and treatment of depression in
eople with chronic illness, and particularly with respect to
iabetes. Despite the recognized importance of this co-morbid
ondition, an estimated 50% of patients remain undiag-
osed and an even greater proportion is left untreated [3,4].
elf-assessment questionnaires can dramatically improve
epression detection rates. Complementing such screening
ith assessments of psychological distress can have an addi-
ional and complementary impact on individual self-care
42,43,74,75]. The choice of screening questionnaire should
lso consider factors such as ease of implementation: quick,
on-invasive and sensitive measures that directly link disease
everity with management.
It is important to emphasize, however, that it is not enough
o screen for depression and refer for treatment if neces-
ary; and the relevant health care professional(s) should follow
p patients in a timely manner. Screening performed out of
he context of a structured disease management program is
nhelpful, and risks setting up the patient and health care
rofessional for failure. Integrating the monitoring of patient
ell-being into routine clinical reviews of people with chronic
edical illness provides a more objective and holistic evalua-
ion; and in conjunction with stepped care and collaborative
are models to help guide management, has the potential to
mprove treatment outcomes without overwhelming existing
esources. Cost-effectiveness needs to be demonstrated, but
n light of potential beneﬁts with regard to improvements in
elf-care behavior and reduced health care utilization, and
he expected introduction of web based CBT, screening for
o-morbid depression may eventually prove to be cost-saving.onﬂicts of interest statement
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